| Autor: |
Wang SA; Department of Pathology, UMass Memorial Medical Center, University of Massachusetts, Worcester, MA, USA. swang5@mdanderson.org, Tang G, Fadare O, Hao S, Raza A, Woda BA, Hasserjian RP |
| Jazyk: |
angličtina |
| Zdroj: |
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2008 Nov; Vol. 21 (11), pp. 1394-402. Date of Electronic Publication: 2008 Sep 12. |
| DOI: |
10.1038/modpathol.2008.142 |
| Abstrakt: |
In the FAB (French-American-British) and WHO (World Heath Organization) classifications, the blasts in erythroleukemia (M6a) are enumerated from the marrow nonerythroid rather than the total-nucleated cells. However, the method for blast calculation in erythroid-predominant myelodysplastic syndrome (erythroblasts>or=50%) is not specified either in the FAB or WHO classifications. We retrieved the files of 74 erythroid-predominant myelodysplastic syndrome patients (17% of all myelodysplastic syndrome) and 192 myelodysplastic syndrome controls (erythroblasts<50%). In erythroid-predominant myelodysplastic syndrome, by enumerating blasts from marrow nonerythroid cells rather than from total nucleated cells, 41 of 74 (55%) cases would be upgraded, either by disease subcategory or International Prognostic Scoring System. Importantly, the patients with <5% blasts demonstrated a superior survival to patients with >or=5% blasts (P=0.002); this distinction was lost when blasts were calculated from total-nucleated cells. Of cases with >or=5% blasts, cytogenetics rather than blast count correlated with survival. We conclude that in erythroid-predominant myelodysplastic syndrome, blast calculation as a proportion of marrow nonerythroid rather than total nucleated cells can better stratify patients into prognostically relevant groups. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
